Advertisement

Hemmstoffe des Renin- Angiotensin-Systems

  • Manfred Anlauf
  • Franz Weber

Zusammenfassung

Hemmstoffe des Renin-Angiotensin-Systems (RAS) gehören zu den erfolgreichsten Arzneimitteln zur Behandlung von Hypertonie, Herz- und Nierenkrankheiten. Angiotensinrezeptorantagonisten gewinnen nach Auslaufen des Patentschutzes mehrerer Sartane weitere Marktanteile. Dagegen verliert erneut deutlich der bisher einzige Renininhibitor.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Investigators ACTIVEI, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ (2011) Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928–938CrossRefGoogle Scholar
  2. Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, Reid CM, Golledge J, Kingwell BA (2013) Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 309:453–460PubMedCrossRefGoogle Scholar
  3. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM (2010) The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 25:3977–3982PubMedCrossRefGoogle Scholar
  4. Anlauf M (2006) Beurteilung von Therapien mit der „number needed to treat”. Dtsch Ärztebl 103:A3254–A3258Google Scholar
  5. Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM (2013) Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. Cmaj 185:1035–1041PubMedCentralPubMedCrossRefGoogle Scholar
  6. Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, B and 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae.de/35/74_Hypertonie_2004_2Auflage.pdfGoogle Scholar
  7. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators (2010) Renal outcomes with diff erent fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 375:1173–1181CrossRefGoogle Scholar
  8. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH (2011a) Antihypertensive drugs and risk of cancer: network metaanalyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol 12:65–82CrossRefGoogle Scholar
  9. Bangalore S, Kumar S, Wetterslev J, Messerli FH (2011b) Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 342:d223–4. doi: 10.1136CrossRefGoogle Scholar
  10. Bangalore S, Kumar S, Messerli FH (2012) When Conventional Heart Failure Therapy is not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist? Congest Heart Fail. doi: 10.1111/chf.12011PubMedGoogle Scholar
  11. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin- receptor blockade versus converting–enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961PubMedCrossRefGoogle Scholar
  12. Bhaskaran K, Douglas I, Evans S, van Staa T, Smeeth L (2012) Angiotensin receptor blockers and risk of cancer: cohort study among people receiving ntihypertensive drugs in UK General Practice Research Database. BMJ 344:e269–7CrossRefGoogle Scholar
  13. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898CrossRefGoogle Scholar
  14. Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C; HYVET Study Group (2012) Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344:1–10Google Scholar
  15. Blood Pressure Lowering Treatment Trialists' Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. The Lancet 356:1955–1964CrossRefGoogle Scholar
  16. Blood Pressure Lowering Treatment Trialists` Collaboration (2007) Blood Pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertension 25:951–958CrossRefGoogle Scholar
  17. Brown MJ (2008) Aliskiren. Circulation 118:773–784PubMedCrossRefGoogle Scholar
  18. Bundesärztekammer, Kassenärztliche B, Arbeitsgemeinschaft derWMedizinischenF (2011): Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter 1. Auflage Version 1.3Google Scholar
  19. Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators (2009) Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 20:893–900PubMedCentralPubMedCrossRefGoogle Scholar
  20. Carey RM (2013) Newly discovered components and actions of the renin-angiotensin system. Hypertension 62:818–822PubMedCrossRefGoogle Scholar
  21. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. The Lancet 366:2026–2033CrossRefGoogle Scholar
  22. Cleland JG, Tendera M, Adamus J, Freemantle, Polonski L, Taylor J; PEP-CHF Investigators (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338–2345PubMedCrossRefGoogle Scholar
  23. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675PubMedCrossRefGoogle Scholar
  24. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B (2011) The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29:4–16PubMedCrossRefGoogle Scholar
  25. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 359:995–1003CrossRefGoogle Scholar
  26. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. The Lancet 360:752–760CrossRefGoogle Scholar
  27. Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet 369:201–207CrossRefGoogle Scholar
  28. European Medicines Agency (2014): PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system. Press Release April 11, 2014; EMA/196502/2014Google Scholar
  29. FDA Drug Safety Communication (2013): FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. 7-3-2013Google Scholar
  30. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E (2000): Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355: 1575–1581Google Scholar
  31. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P (2013): Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892–1903Google Scholar
  32. Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX (2013): Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 310: 2544–2553Google Scholar
  33. Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M (2014): Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet 383: 1889–1898Google Scholar
  34. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G (2009): Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606–1617Google Scholar
  35. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet 362:772–776CrossRefGoogle Scholar
  36. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907–917PubMedCrossRefGoogle Scholar
  37. Hasenfuss G, Edelmann F, Wachter R (2013) Empfehlung zur Herzinsuffizienz Was gibt es Neues? Internist (Berl) 54:1141–1151CrossRefGoogle Scholar
  38. Heerspink HL, de Zeeuw D (2010) Composite renal endpoints: was ACCOMPLISH accomplished? The Lancet 375:1140–1142CrossRefGoogle Scholar
  39. Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, Cooper M, Grobbee DE, Mancia G, Mogensen CE, Neal B, Chalmers J; ADVANCE Collaborative Group (2010) Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31:2888–2896CrossRefGoogle Scholar
  40. Hermida RC, Ayala DE, Mojón A, Fernández JR (2011) Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 22:2313–2321PubMedCentralPubMedCrossRefGoogle Scholar
  41. Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, Wu Y, Tang H, Xu D (2014) Association of all-cause and cardiovascular mortality with prehypertension: a meta- analysis. Am Heart J 167(160–168):e–1Google Scholar
  42. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, Makino H; ORIENT study investigators (2011) Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 54:2978–2986PubMedCentralPubMedCrossRefGoogle Scholar
  43. Jamerson K, Weber MA, Bakris GL, Dahlöf B et al ACCOMPLISH Trial Investigators (2008): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 359: 2417–2428Google Scholar
  44. Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA (2011) Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 57:174–179PubMedCrossRefGoogle Scholar
  45. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet 363:2022–2031CrossRefGoogle Scholar
  46. Julius S, Nesbitt SD, Egan BM. for the Trial of Preventing Hypertension (TROPHY) Study Investigators (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685–1697PubMedCrossRefGoogle Scholar
  47. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H (2009) Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker- based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 30:1203–1212PubMedCrossRefGoogle Scholar
  48. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet 374:1840–1848CrossRefGoogle Scholar
  49. Kunz R, Friedrich C, Wolbers M, Mann JFE (2008) Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48PubMedCrossRefGoogle Scholar
  50. Lakhdar R, Al-Mallah MH, Lanfear DE (2008) Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 14:181–188PubMedCrossRefGoogle Scholar
  51. Laverman GD, Navis G, Henning RH, de Jong D, de Zeeuw D (2002): Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62: 1020– 1025Google Scholar
  52. Levy BI (2004) Can angiotensin II Type 2 receptors have deleterious effects in cardiovascular disease? Circulation 109:8–13PubMedCrossRefGoogle Scholar
  53. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–1462PubMedCrossRefGoogle Scholar
  54. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al for the SCOPE Study Group (2003): The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21: 875–886Google Scholar
  55. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P; PHARAO study group (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26:1487–1496CrossRefGoogle Scholar
  56. Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW (2010) Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit 15:195–204PubMedCrossRefGoogle Scholar
  57. Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V (2013) Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185:949–957PubMedCentralPubMedCrossRefGoogle Scholar
  58. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH (2013): Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials BMJ Jan 28;346:f360. doi: 10.1136Google Scholar
  59. Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study (2004) Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 26:855–865PubMedCrossRefGoogle Scholar
  60. Mann JFE, Schmieder RE, McQueen M, Dyal L et al on behalf of the ONTARGET investigators (2008): Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547–553Google Scholar
  61. Mann JFE, Schmieder RE, Dyal L, McQueen MJ et al (2009) Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 151(1–10):W1–W2CrossRefGoogle Scholar
  62. Marott SC, Nielsen SF, Benn M, Nordestgaard BG (2014) Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 35:1205–1214PubMedCrossRefGoogle Scholar
  63. Maschio G, Albert D, Ganin G, Locatelli F, Mann JFE et al (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945PubMedCrossRefGoogle Scholar
  64. Massie BM, Carson PE, McMurray JJ, Komajda M et al I-PRESERVE Investigators (2008): Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 359: 2456–2467.Google Scholar
  65. McMurray JJ, Östergren J, Swedberg K, Granger CB, Held P, Eric L, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, for the CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. The Lancet 362:767–771CrossRefGoogle Scholar
  66. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) Study. Brit Med J 321:1440–1444PubMedCentralPubMedCrossRefGoogle Scholar
  67. National Collaborating Centre for Chronic Conditions (2006): Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians. Internet: http://guidance.nice. org.uk/CG34/guidance/pdf/EnglishGoogle Scholar
  68. Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE (2013) Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 310:1135–1144PubMedCrossRefGoogle Scholar
  69. Oghlakian GO, Sipahi I, Fang JC (2011) Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc 86:531–539PubMedCentralPubMedCrossRefGoogle Scholar
  70. Padwal R, Lin M, Etminan M, Eurich DT (2014) Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 63:977–983PubMedCrossRefGoogle Scholar
  71. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446PubMedCrossRefGoogle Scholar
  72. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2204–2213PubMedCrossRefGoogle Scholar
  73. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators (2003a) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906CrossRefGoogle Scholar
  74. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees (2003b) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet 362:759–766CrossRefGoogle Scholar
  75. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. The Lancet 355:1582–1587CrossRefGoogle Scholar
  76. Pitt B (2004) ACE inhibitors for patients with vascular disease without left ventricular dysfunction – may they rest in PEACE? N Engl J Med 351:2115–2117PubMedCrossRefGoogle Scholar
  77. Rector TS, Carson PE, Anand IS, McMurray JJ, Zile MR, McKelvie RS, Komajda M, Kuskowski M, Massie BM; I-PRESERVE Trial Investigators (2012) Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart Fail 5:217–225PubMedCrossRefGoogle Scholar
  78. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA (2012) Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87:732–738PubMedCentralPubMedCrossRefGoogle Scholar
  79. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951PubMedCrossRefGoogle Scholar
  80. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E; SCAST Study Group (2011) The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. The Lancet 377:741–750CrossRefGoogle Scholar
  81. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16:3038–3045PubMedCrossRefGoogle Scholar
  82. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt MW (2007) Renin angiotensin system and cardiovascular risk. The Lancet 369:1208–1219CrossRefGoogle Scholar
  83. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010) Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta- analysis. J Am Coll Cardiol 55:2299–2307PubMedCrossRefGoogle Scholar
  84. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group (2003) The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 234:1699–1703CrossRefGoogle Scholar
  85. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group (2005): Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218– 1226Google Scholar
  86. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11:627–636PubMedCentralPubMedCrossRefGoogle Scholar
  87. Staessen JA, Li Y, Thijs L, Wang JG (2005) Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 28:385–407PubMedCrossRefGoogle Scholar
  88. Staessen JA, Richart T, Wang Z, Thijs L (2010) Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients. Hypertension 55:819–831PubMedCrossRefGoogle Scholar
  89. Svensson P, de Faire U, Sleight P, Yusuf S, Jan Östergren J (2001): Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38: e28–e32Google Scholar
  90. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997CrossRefGoogle Scholar
  91. The DREAM Trial Investigators (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562CrossRefGoogle Scholar
  92. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet 362:782–788CrossRefGoogle Scholar
  93. The GISEN Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The Lancet 349:1857–1863CrossRefGoogle Scholar
  94. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153CrossRefGoogle Scholar
  95. The Indian Polycap Study (TIPS) (2009) Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. The Lancet 373:1341–1351CrossRefGoogle Scholar
  96. The ONTARGET Investigators (2008) Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559CrossRefGoogle Scholar
  97. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The Lancet 372:1174–1183CrossRefGoogle Scholar
  98. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA (2011) Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305:913–922PubMedCrossRefGoogle Scholar
  99. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E (2012) Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 33:2088–2097PubMedCentralPubMedCrossRefGoogle Scholar
  100. Verma S, Strauss M (2004) Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction – and patients may need to be told. BMJ 329:1248–1249PubMedCentralPubMedCrossRefGoogle Scholar
  101. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB (2005a) Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:705–711CrossRefGoogle Scholar
  102. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005b) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:712–719CrossRefGoogle Scholar
  103. Walker AM, Liang C, Clifford CR, Parker C, Feldman A (2014) Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin- converting enzyme inhibitors. Pharmacoepidemiol Drug Saf 23:348–356PubMedCrossRefGoogle Scholar
  104. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B (2013) Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. The Lancet 381:537–545CrossRefGoogle Scholar
  105. White HD (2003) Commentary. Candesartan and heart failure: the allure of CHARM. The Lancet 362:754–755CrossRefGoogle Scholar
  106. Wing LM, Reid MC, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group (2003) A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:583–592PubMedCrossRefGoogle Scholar
  107. Yusuf S (2002) From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89(2A):1–8A–25AGoogle Scholar
  108. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet 362:777–781CrossRefGoogle Scholar
  109. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S for the PRoFESS Study Group (2008) Telmisartan to prevent recurrent stroke and cardiovascular Events. N Engl J Med 359:1225–1237PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Manfred Anlauf
    • 1
  • Franz Weber
    • 2
  1. 1.Bremerhaven
  2. 2.St.Walburga KrankenhausMeschede

Personalised recommendations